FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Legorreta Pablo G.		 2. Issuer Name and Ticker or Trading Symbol

Royalty Pharma plc [ RPRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO, Chairman of the Board
(Last)          (First)          (Middle)

C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/16/2023
(Street)

NEW YORK, NY 10022		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A ordinary shares 5/16/2023  P(1)  160388 A$33.5669 (2)160388 I By Legorreta 2023 SR Trust 
Class A ordinary shares 5/17/2023  P(1)  69612 A$32.9411 (3)230000 I By Legorreta 2023 SR Trust 
Class A ordinary shares         63795 D  
Class A ordinary shares         460139 I By Legorreta Investments LLC 
Class A ordinary shares         1284590 I By GST-Exempt Legorreta 2012 Family Trust 
Class A ordinary shares         41306 I By GST-Exempt Legorreta 2020 Family Trust 
Class A ordinary shares         10000 I By Child 
Class A ordinary shares         10000 I By Child 
Class A ordinary shares         123310 I By IRRA 
Class A ordinary shares         118500 I By SEP/IRA 
Class A ordinary shares         1040410 I By Legorreta Children 2002 Trust 
Class A ordinary shares         6930 I By Spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.
(2) The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $33.48 to $33.76. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
(3) The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.70 to $33.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Legorreta Pablo G.
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
NEW YORK, NY 10022		XXCEO, Chairman of the Board
Signatures
/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta5/17/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Royalty Pharma Charts.
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Royalty Pharma Charts.